PainResearch Phase

Nociceptin / Orphanin FQ

Endogenous peptide

Overview

Nociceptin, also known as orphanin FQ, is a 17-amino acid peptide that acts as the endogenous ligand for the nociceptin/orphanin FQ peptide (NOP) receptor, a member of the opioid receptor family with distinct pharmacology. Despite structural similarity to dynorphin A, nociceptin does not bind classical opioid receptors.

Mechanism of Action

Its effects on pain are complex and context-dependent, producing analgesia at the spinal level but pronociceptive or hyperalgesic effects at supraspinal sites. The peptide also modulates stress, anxiety, and reward pathways..

Research Summary & Key Findings

Preclinical research has extensively characterized nociceptin's bidirectional effects on pain processing across different anatomical sites and pain models. Clinical development has focused on small-molecule NOP receptor agonists and mixed NOP/mu-opioid ligands rather than the native peptide. Phase 2 trials of cebranopadol, a dual NOP/mu agonist, have shown analgesic efficacy in chronic pain, though nociceptin itself remains a research tool.

Clinical Status

Research Phase

Nociceptin / Orphanin FQ is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Endogenous peptide

Related Peptides in Pain

Find a Provider

Find a verified provider who offers Nociceptin / Orphanin FQ therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Nociceptin / Orphanin FQ.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.